Orphazyme A/S ( ORPH) Stock. Should you Buy or Sell? $ 0.87
0.00 (0.00 %)
Orphazyme A/S Analysis
Updated on 10-09-2022| Symbol | ORPH |
| Price | $0.87 |
| Beta | 0.802 |
| Volume Avg. | $1.38 M |
| Market Cap | $37.27 M |
| 52 Week Range | $0.5101 - $77.77 |
Orphazyme A/S opened the day at $0.87 which is 0.00 % on yesterday's close. Orphazyme A/S has a 52 week high of $77.77 and 52 week low of $0.5101, which is a difference of $77.2599. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $37.27 M and total net profit is $0 which means the company is trading at inf times profit to market capitalization. Theoretically, if you were to buy Orphazyme A/S for $37.27 M, it would take 15 years to get your money back. Orphazyme A/S are in the Biotechnology space which will have a sweet spot and industry standard for net profit multiples.
Price Chart
Financials
Orphazyme A/S Stock Forecast - Is Orphazyme A/S a Buy or Sell?
| DCF Score | Strong Buy | |
| ROE Score | Strong Sell | |
| ROA Score | Sell | |
| DE Score | Neutral | |
| PE Score | Sell | |
| PB Score | Strong Buy | |
| Overall Recommendation | Neutral |
Growth and Value
| PE Ratio | -0.227 |
| Dividend Yiel | 0.000 |
| Net Profit Margin | 0.000 |
Valuing Orphazyme A/S
| Price Book Value Ratio | 0.660 | Price To Book Ratio | 0.660 |
| Price To Sales Ratio | 0.000 | Price Earnings Ratio | -0.227 |
How liquid is Orphazyme A/S
| Current Ratio | 1.805 |
| Quick Ratio | 1.805 |
Debt
| Debt Ratio | 0.610 | Debt Equity Ratio | 1.567 |
| Long Term Debt To Capitalization | 0.119 | Total Debt To Capitalization | 0.260 |
Latest news about Orphazyme A/S
Orphazyme A/S (NASDAQ: ORPH) has decided to withdraw its European Marketing Application for arimoclomol for Niemann-Pick disease Type C (NPC) ahead of a final vote and opinion by the CHMP scheduled for later this month. "Today's decision to withdraw the MAA enables us to.
After Orphazyme announced that it would withdraw the application for approval of its drug and delist its ADSs, ORPH stock is falling. The post Dear ORPH Stock Fans, Mark Your Calendars for March 31 appeared first on InvestorPlace.
Orphazyme A/S's (NASDAQ: ORPH) board of directors has called for a court-mediated restructuring, prompting the second round of layoffs in less than a year. The in-court restructuring will determine whether any operations can continue if the Company can raise any capital or if it is.
Orphazyme A/S (NASDAQ: ORPH) has been notified by the Committee for Medicinal Products for Human Use (CHMP) of a negative trend vote on arimoclomol application following an Oral Explanation. The application covers arimoclomol for Niemann-Pick disease type C (NPC), a rare genetic.
Orphazyme (ORPH) is looking to resubmit its NDA for arimoclomol to the FDA for the treatment of Niemann-Pick disease type C in the United States. Shares rise.
About Orphazyme A/S
Description :
Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on the amplification of heat-shock proteins to develop and commercialize therapeutics for diseases caused by protein misfolding and aggregation, and lysosomal dysfunction, including lysosomal storage and neuromuscular degenerative diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, Inclusion Body Myositis, and Gaucher disease. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark.
